|
Resolution: standard / high Figure 4.
The expression of self-complementary AAV2-TTR-RB15 (scAAV2-TTR-RB15) vector in HepG2
cells. (A). The drawings depict the predicted conformations of monomer and dimer of
TTR-RB15 virions. (B). Alkaline agarose gel electrophoresis (0.8%) of scAAV2-TTR-RB15
viral DNA, followed by Southern blot analysis, hybridized with 32P-labeled RB15 probe. The positions of monomer and dimmer are shown. (C). Comparison
of the ribozyme RB15 RNA levels between cells treated with non-modified parent rAAV2-TTR-RB15
vectors and cells treated with scAAV2-TTR-RB15 vectors at days 1 and 3 after treatment.
Total RNA was extracted from HepG2 cells treated with either non-modified parent AAV2-TTR-RB15
or scAAV2-TTR-RB15 vectors. The levels of RB15 RNA were determined using one-step
RT-PCR and analyzed by 2% agarose gel electrophoresis. The same samples were also
determined by PCR only. The position of RB15 RNA is shown. (D). Comparison of apoB
mRNA levels in HepG2 cells at day-3 after treatment with non-modified parent rAAV2-TTR-RB15
vectors or with modified scAAV2-TTR-RB15 vectors. ApoB mRNA was determined by real-time
quantitative RT-PCR. The apoB mRNA levels were normalized with 18S RNA. The results
are expressed as % of cells treated with inactive RB15-mutant. The results are shown
as means ± standard deviation of triple experiments. Experiment of cells infected
with adenovirus-RB15-mutant, adenovirus-RB15 (positive control) are performed at the
same time and used as a positive comparison purpose. Cells treated with parent-rAAV2-TTR-RB15-mutant,
parent rAAV2-TTR-RB15, scAAV2-TTR-RB15-mutant, and scAAV2-TTR-RB15 are shown. The
p values analyzed by student t-test are shown. ns = not significant
Zhong et al. Genetic Vaccines and Therapy 2004 2:5 doi:10.1186/1479-0556-2-5 |